Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.37 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15461571 | 0.84 | RORC (0.43) | RORCKDM4EALDH1A1MAPTRXFP1 | |
| SCHEMBL20478920 | 0.82 | CA2 (0.47) | RORCKDM4EALDH1A1MAPTRXFP1 | |
| SCHEMBL2904147 | 0.82 | RORC (0.45) | RORCKDM4EALDH1A1MAPTRXFP1 | |
| SCHEMBL10153951 | 0.79 | RORC (0.41) | RORCKDM4EALDH1A1MAPTRXFP1 | |
| SCHEMBL27036985 | 0.79 | GAA (0.50) | MAPTL3MBTL1 | |
| SCHEMBL2444098 | 0.78 | RORC (0.40) | RORCKDM4EALDH1A1MAPTRXFP1 | |
| SCHEMBL630954 | 0.76 | L3MBTL1 (0.54) | KDM4EALDH1A1MAPTL3MBTL1CA2 | |
| SCHEMBL22831319 | 0.75 | NOTUM (0.44) | ALDH1A1L3MBTL1HTR6 | |
| SCHEMBL13222509 | 0.74 | NQO2 (0.47) | RORCKDM4EALDH1A1MAPTRXFP1 | |
| SCHEMBL19682913 | 0.71 | L3MBTL1 (0.42) | L3MBTL1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692094-A1 | SULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Beijing Konruns Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024133499-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2024-06-27 | — | — | WO | disclosed |
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | GENENTECH, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| CN-111247136-A | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating diseases and disorders associated with IRE1 | 吉宁特有限公司 | 2020-06-05 | — | — | CN | disclosed |
| WO-2018166528-A1 | PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS | GENENTECH, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180265497-A1 | PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS | GENENTECH, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
| EP-2828238-B1 | SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES | ADAMED SP ZOO (PL) | 2016-05-25 | — | — | EP | disclosed |
| US-9340522-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9120767-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z.O.O. (PL) | 2015-09-01 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| EP-2099763-B1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| WO-2010055083-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2009142984-A1 | ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009126675-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| CN-101541753-A | 2-Aminoquinolines as 5-HT(5A) receptor antagonists | HOFFMANN LA ROCHE (CH) | 2009-09-23 | — | — | CN | disclosed |
| EP-2099763-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20080146567-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | US | disclosed |
| WO-2008068157-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | XBP1, ERN1, ATF4 | RORC 153/4885KDM4E 3778/4885ALDH1A1 2916/4885 |
| US-20080146567-A1 | QUINOLINES | HTR5A, HTR2B, HTR2C | RORC 2448/4885KDM4E 1571/4885ALDH1A1 1619/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | RORC 1692/4885KDM4E 2721/4885ALDH1A1 2086/4885 |
| US-20180265497-A1 | PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS | XBP1, ERN1, ATF4 | RORC 153/4885KDM4E 3778/4885ALDH1A1 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.